Assessment of immunological anti‐platelet factor 4 antibodies for vaccine‐induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients

Emmanuel J Favaloro, Joanne Clifford,Emma Leitinger,Michael Parker, Pauline Sung,Sanjeev Chunilal,Huyen Tran,Geoffrey Kershaw, Suki Fu,Freda Passam, Monica Ahuja,Shir Jing Ho, Elizabeth Duncan,Olivia Yacoub,Chee Wee Tan, Lisa Kaminskis, Natasha Modica,Dominic Pepperell, Leanne Ballard,Lisa Clarke,Christine S M Lee,Elizabeth E Gardiner,Philip Young-Ill Choi,Ibrahim Tohidi-Esfahani,Robert Bird, Timothy Brighton,Vivien M Chen

Journal of Thrombosis and Haemostasis（2022）

引用 17|浏览12

暂无评分

摘要

To our knowledge, this is the largest multicenter evaluation of anti-PF4 testing for investigation of VITT. Discrepancies in test results (ELISA vs. ELISA or ELISA vs. functional assay) in some patients highlighted limitations in relying on single methods (ELISA and functional) for PF4 antibody detection in VITT, and also highlights the variability in phenotypic test presentation and pathomechanism of VITT.

查看译文

关键词

COVID‐19 vaccine,enzyme‐linked immunosorbent assay,platelet factor 4,thrombocytopenia,thrombosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要